Chengdu Diaoyao Group

Chengdu Di'ao Pharmaceutical Group is a prominent Chinese pharmaceutical enterprise founded in 1988 by the Chengdu Institute of Biology of the Chinese Academy of Sciences. The company is best known for its flagship product, Di'ao Xinxuekang, a cardiovascular medicine derived from natural steroidal saponins that became the first Chinese herbal medicine to receive marketing authorization in the European Union. Di'ao Group operates as a comprehensive healthcare entity with business segments spanning drug R&D, manufacturing, and sales, as well as health food and cosmetics. Its research focus includes cardiovascular health, oncology, and immunology, utilizing both traditional Chinese medicine principles and modern chemical synthesis. The group maintains a significant presence in the Chinese domestic market and continues to pursue international expansion for its natural product portfolio.